New combo therapy aims to improve survival in hard-to-treat rectal cancer
NCT ID NCT07594925
First seen May 20, 2026 · Last updated May 24, 2026 · Updated 1 time
Summary
This study tests whether adding an immunotherapy drug (sintilimab) to standard short-course radiation and chemotherapy can improve long-term survival in people with a common type of locally advanced rectal cancer (MSS type). About 130 adults with stage II or III rectal cancer will be randomly assigned to receive either the standard treatment or the standard treatment plus immunotherapy before and after surgery. The goal is to see if the new combination helps keep the cancer from coming back.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tianjin Medical University Cancer Institute & Hospital, Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer
RECRUITINGTianjin, 300060, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.